Abstract
BackgroundThe combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have